Patents by Inventor Muneto Mogi

Muneto Mogi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197941
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Philippe BOLDUC, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • Substituted aminobutyric derivatives as neprilysin inhibitors
    Patent number: 9603819
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 28, 2017
    Assignee: NOVARTIS AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS
    Publication number: 20150174089
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 2, 2015
    Publication date: June 25, 2015
    Applicant: NOVARTIS AG
    Inventors: Gary Mark COPPOLA, Yuki IWAKI, Rajeshri KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI, Robert SUN
  • Substituted aminobutyric derivatives as neprilysin inhibitors
    Patent number: 9006249
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
    Patent number: 8877815
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Qian Liu, Muneto Mogi, Nikolaus Schiering, Robert Sun
  • SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS
    Publication number: 20140296240
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Gary Mark COPPOLA, Yuki IWAKI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI, Robert SUN
  • Organic compounds
    Patent number: 8759365
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: June 24, 2014
    Assignee: Novartis AG
    Inventors: Muneto Mogi, Toshio Kawanami, Ken Yamada, Kayo Yasoshima, Hidetomo Imase, Takahiro Miyake, Osamu Ohmori
  • METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS
    Publication number: 20140134262
    Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.
    Type: Application
    Filed: July 6, 2012
    Publication date: May 15, 2014
    Inventors: Yoshie Arai, Margaret Elizabeth Brousseau, Jessie Gu, Tomoko Hayashi, Hironobu Mitani, Muneto Mogi, Kazuhiko Nonomura, Ken Yamada
  • Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
    Patent number: 8642635
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: February 4, 2014
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
  • 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
    Patent number: 8440682
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: May 14, 2013
    Assignee: Novartis AG
    Inventors: Muneto Mogi, Ken Yamada, Kayo Yasoshima, Toshio Kawanami, Ichiro Umemura, Yuki Iwaki, Hongbo Qin, Hidetomo Imase
  • Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
    Publication number: 20130096168
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 5, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS AG
    Inventors: Yuki IWAKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI
  • Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives
    Patent number: 8420641
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: April 16, 2013
    Assignee: Novartis AG
    Inventors: Muneto Mogi, Ken Yamada, Kayo Yasoshima, Toshio Kawanami, Ichiro Umemura, Yuki Iwaki, Hongbo Qin, Hidetomo Imase
  • Substituted aminopropionic derivatives as neprilysin inhibitors
    Patent number: 8394853
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: March 12, 2013
    Assignee: Novartis AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
    Patent number: 8377978
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: February 19, 2013
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
  • ORGANIC COMPOUNDS
    Publication number: 20120264773
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Application
    Filed: June 7, 2012
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Muneto MOGI, Ken YAMADA, Kayo YASOSHIMA, Toshio KAWANAMI, Ichiro UMEMURA, Yuki IWAKI, Hongbo QIN, Hidetomo IMASE
  • Substituted Aminobutyric Derivatives as Neprilysin Inhibitors
    Publication number: 20120252830
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 7, 2012
    Publication date: October 4, 2012
    Applicant: NOVARTIS AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • Substituted aminobutyric derivatives as neprilysin inhibitors
    Patent number: 8263629
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • ORGANIC COMPOUNDS
    Publication number: 20120208816
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Muneto MOGI, Ken YAMADA, Kayo YASOSHIMA, Toshio KAWANAMI, Ichiro UMEMURA, Yuki IWAKI, Hongbo QIN, Hidetomo IMASE
  • Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
    Publication number: 20120202862
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: NOVARTIS AG
    Inventors: Yuki IWAKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI
  • Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
    Patent number: 8222286
    Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi